<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Aggressive mature B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (BCL) sharing features of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) (intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) but deviating with respect to one or more characteristics are increasingly recognized </plain></SENT>
<SENT sid="1" pm="."><plain>The limited knowledge about these biologically <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> <z:hpo ids='HP_0002665'>lymphomas</z:hpo> hampers their assignment to a known entity, raising incertitude about optimal treatment approaches </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore searched for discriminative, prognostic, and predictive factors for their better characterization </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: We analyzed 242 cytogenetically defined aggressive mature BCL for differential protein expression </plain></SENT>
<SENT sid="4" pm="."><plain>Marker selection was based on recent gene-expression profile studies </plain></SENT>
<SENT sid="5" pm="."><plain>Predictive models for diagnosis were established and validated by a different set of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: CSE1L- and inhibitor of DNA binding-3 (ID3)-overexpression was associated with the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and signal transduction and transcription-3 (STAT3) with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> (P&lt;0.001 for <z:hpo ids='HP_0000001'>all</z:hpo> markers) </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three markers were associated with patient outcome in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>A new algorithm discriminating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> emerged, including the expression of CSE1L, STAT3, and MYC translocation </plain></SENT>
<SENT sid="9" pm="."><plain>This 'new classifier' enabled the identification of patients with intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> who benefited from intensive chemotherapy regimens </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The proposed algorithm, which is based on markers with reliable staining properties for routine diagnostics, represents a novel valid tool in separating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Most interestingly, it allows segregating intermediate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> into groups with different treatment requirements </plain></SENT>
</text></document>